Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of liriope spicata saponin B in preparation of medicine for treating skin inflammation

A technology of ryeposide saponin and skin inflammation, applied in the field of application of ryeposide saponin B in the preparation of medicines for treating skin inflammation, can solve problems such as the application of ryeposide saponin B that has not been reported in the literature, and achieve good protection effect, reduce the effect of side effects

Pending Publication Date: 2020-09-15
WUYI UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no literature report on the application of Ophioside B in the treatment of skin inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of liriope spicata saponin B in preparation of medicine for treating skin inflammation
  • Application of liriope spicata saponin B in preparation of medicine for treating skin inflammation
  • Application of liriope spicata saponin B in preparation of medicine for treating skin inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The effect of the different concentrations of ryeposide B on the activity of HaCaT cells in Example 1

[0032] (1) Experimental method

[0033] HaCaT keratinocytes (2×10 4 Cells / ml) were seeded in 35mm culture dishes and placed in 5% CO 2 , and cultured in a 37°C incubator for 24 hours to allow the cells to attach to the culture dish. Set the concentration of ryeposide B to 0.5 μM, 1.0 μM, 2.0 μM, 4.0 μM, 8.0 μM, and treat the cells for 48 hours. Digest HaCaT cells from the culture dish with trypsin, add DMEM medium containing 10% heat-inactivated FBS and antibiotics (100 units / mL penicillin, 100 μg / mL streptomycin) to make cell suspension, press 80 μL After the cell suspension was mixed with 20 μL of trypan blue solution (0.04 g / mL) for 2 minutes, the number of viable cells after treatment was measured with a hemocytometer under a light microscope. Blue cells are considered dead cells, while unstained cells are considered live cells. Cell viability=(total number o...

Embodiment 2

[0036] Example 2 The effect of ryeposide B on the level of CCL5 in cells treated with inflammatory cytokine composition

[0037] (1) Experimental method

[0038] HaCaT keratinocytes (1×10 6 cells / ml) were seeded in 6-well plates and placed in 5% CO 2, and cultured in a 37°C incubator for 24 hours to allow the cells to attach to the culture dish. HaCaT cells were stimulated with a combination of inflammatory cytokines interleukin-6 (15 ng / mL), interleukin-1β (10 ng / mL) and tumor necrosis factor-α (10 ng / mL), and the concentration of ryeposide B was set to 0.5 μM , 1.0 μM, 2.0 μM, 4.0 μM, 8.0 μM, the cells were treated for 24 hours. According to the instructions of the enzyme-linked immunosorbent assay kit, the level of CCL5 in the culture supernatant was determined by using it.

[0039] (2) Experimental results

[0040] like figure 2 As shown, ryeposide B at 0.5uM had no effect on CCL5 levels. At 1.0 uM, ryeposide B had some effect on CCL5, but did not reach statistical...

Embodiment 3

[0042] Example 3 Effects of Limeposide B on CCL17 Levels in Cells Treated with Inflammatory Cytokine Composition

[0043] (1) Experimental method

[0044] HaCaT keratinocytes (1×10 6 cells / ml) were seeded in 6-well plates and placed in 5% CO 2 , and cultured in a 37°C incubator for 24 hours to allow the cells to attach to the culture dish. Stimulate HaCaT cells with a combination of inflammatory cytokines interleukin-6 (15 ng / mL), interleukin-1β (10 ng / mL) and tumor necrosis factor-α (10 ng / mL), and set the concentration of ryeposide B to 0.5 μM, 1.0 μM, 2.0 μM, 4.0 μM, 8.0 μM, cells were treated for 24 hours. According to the instructions of the enzyme-linked immunosorbent assay kit, the level of CCL17 in the culture supernatant was determined by using it.

[0045] (2) Experimental results

[0046] like image 3 As shown, low doses of ryeposide B (0.5 and 1.0 μM) did not significantly reduce the level of CCL17, 2.0 μM of ryeposide B moderately decreased the level of CCL...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biological medicines, in particular to application of liriope spicata saponin B in preparation of a medicine for treating skin inflammation. The research finds that various inflammatory cytokines can induce skin cell inflammatory reaction, so that the levels of CCL5, CCL17 and CCL22 are significantly increased. HaCaT cells are treated by using the liriope spicata saponin B, so that the levels of CCL5, CCL17 and CCL22 can be reduced, the inflammatory reaction induced by combination of the inflammatory cytokines can be inhibited, and a new way is provided for research and development of a new medicine for resisting the skin inflammation induced by various inflammatory cytokines.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of a kind of ryeposide B in the preparation of medicine for treating skin inflammation. Background technique [0002] The skin covers the surface of the body and is the first important barrier to protect the body from external damage. Skin damage can take many forms. Currently, the pathogenesis and development mechanisms of these skin lesions are unclear. However, it is well known that inflammatory cytokines are involved in the pathogenesis of inflammatory skin lesions. There have been numerous reports of skin lesions, including inflammation and rashes, in patients with COVID-19 around the world. In COVID-19 virus infection, many patients experience an overreaction of the immune system to the infection, which leads to elevated levels of inflammatory cytokines and Called a cytokine storm. The production of a large number of inflammatory cytokines can lead to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P29/00A61P17/00
CPCA61K31/7048A61P29/00A61P17/00
Inventor 王潇郑希李东利徐学涛吴盼盼刘文峰马于然任想
Owner WUYI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com